<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">842</article-id><article-id pub-id-type="doi">10.36691/RJA842</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Controlled trials of efficacy and safety of allergen-specific immunotherapy: historical aspects</article-title><trans-title-group xml:lang="ru"><trans-title>Контролируемые исследования эффективности и безопасности аллергенспецифической иммунотерапии: исторический аспект</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vorob'eva</surname><given-names>Ol'ga Vadimovna</given-names></name><name xml:lang="ru"><surname>Воробьева</surname><given-names>Ольга Вадимовна</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГБУ «ГНЦ Институт иммунологии» ФМБА России</p></bio><email>ptashka095@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gushchin</surname><given-names>I S</given-names></name><name xml:lang="ru"><surname>Гущин</surname><given-names>И С</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГБУ «ГНЦ Институт иммунологии» ФМБА России</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Vorobyeva</surname><given-names>O V</given-names></name><bio xml:lang="en"><p>Institute of Immunology</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Gushchin</surname><given-names>I S</given-names></name><bio xml:lang="en"><p>Institute of Immunology</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ФГБУ «ГНЦ Институт иммунологии» ФМБА России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute of Immunology</institution></aff><aff><institution xml:lang="ru"></institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2011</year></pub-date><volume>8</volume><issue>4</issue><issue-title xml:lang="en">NO4 (2011)</issue-title><issue-title xml:lang="ru">№4 (2011)</issue-title><fpage>3</fpage><lpage>14</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2011, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2011, Фармарус Принт Медиа</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2013-12-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/842">https://rusalljournal.ru/raj/article/view/842</self-uri><abstract xml:lang="ru"><p>в работе рассмотрены контролируемые исследования аллергенспецифической иммунотерапии (асит)
начиная с 80-х гг. до 2010 г. проанализированы отдельные двойные слепые, плацебо-контролируемые
исследования, мета-анализы, Кокрановские обзоры, согласительные документы, рекомендации, национальные и международные руководства. проведен сравнительный анализ эффективности и безопасности
подкожной и сублингвальной асит.</p></abstract><kwd-group xml:lang="ru"><kwd>аллергенспецифическая иммунотерапия</kwd><kwd>контролируемые исследования</kwd><kwd>исторический анализ</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Abramson M.J., Puy R.M., Weiner J.M. Injection allergen immunotherapy for asthma. Cockrane Database Syst. Rev. 2010, v. (8), CD001186.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Calderon M.A., Casale Th.B., Togias A. et al. Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to regulation and beyond. J. Allergy Clin. Immunol. 2011, v. 127, p. 30-38.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>BSACI Position Paper on Immunotherapy. Clin. Exp. Allergy. 1993, v. 23 (Suppl. 3), p. 1-44.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Frew A.J. Injection immunotherapy. British Society for Allergy and Clinical Immunology. Working Party. BMJ. 1993, v. 307, p. 919-923.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Global Strategy for Asthma Management and Prevention. WHO/NHLBI workshop report. National Institutes of Health, National Heart, Lung and Blood Institute; 1995. Publication no. 95-3659.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Guidelines for the use of allergen immunotherapy. Canadian Society of Allergy and Clinical Immunology. CMAJ. 1995, v. 152, p. 1413-1419.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. Allergy. 1994 (Suppl. 19), p. 1-34.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Malling H. Immunotherapy. Position paper of the EAACI. Allergy. 1988, v. 43 (Suppl. 6), p. 9-33.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Malling H.J., Weeke B. Position paper: immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy. 1993, v. 48, p. 7-35.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Van Cauwenberger P., Bachert C., Passalacqua G. et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy. 2000, v. 55, p. 116-134.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Warner J.O. Hyposensitization in asthma: a review. J. R. Soc. Med. 1981, v. 74, p. 60-65.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Bousquet J., Lockey R.F., Malling H.J. (Eds.) WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: 27-29 January 1997. Allergy. 1998, v. 53 (Suppl. 44), p. 1-42.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Canonica G.W., Baena-Cagnani C.E., Bousquet J. et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: a statement of a World Allergy Organisation (WAO) Taskforce. Allergy. 2007, v. 62, p. 317-324.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Canonica G.W., Bousquet J., Casale T. et al. Sub-lingual immunotherapy: World Allergy Organisation Position Paper 2009. Allergy. 2009, v. 64, p. 1-59.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Cox L., Nelson H., Lockey R. et al. Allergen immunotherapy: a practice parameter third update. J. Allergy Clin. Immunol. 2011, v. 127, p. 1-55. Epub 2010 Dec 3.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Cox L., Li J.T., Nelson H. et al. Allergen immunotherapy: a practice parameter second update. J. Allergy Clin. Immunol. 2007, v. 120, p. 25-85.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Immunotherapy. The Australian Society of Clinical Immunology and Allergy [Электронный ресурс]: www.allergy.org.au/ content/view/148/128/ (Дата обращения - 09.03.2011).</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Joint task force for practical parameters. American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter. Ann. Allergy, Asthma, Immunol. 2003, v. 90 (Suppl. 1), p. 1-40.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kleine-Tebbe J. et al. Die spezifische Immunotherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen: Leitlinie der Deutschen Gesellschaft fuer Allergologie und klinische Immunologie (DGAKI), des Aerzteverbandes Deutscher Allergologen (ADA) und der Gesellschaft fuer paediatrische Allergologie und Umweltmedizin (GPA). Allergol. J. 2006, v. 15, p. 56-74.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Leith E. et al. Consensus guidelines on practical issues of immunotherapy - Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy, Asthma, Clin. Immunol. 2006, v. 2, p. 47-61.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Passalacqua G., Ledford D., Cox L. et al. Allergen-specific immunotherapy. In: WAO white book on allergy, p. 110-115 [Электронный ресурс]: www.worldallergy.org/publications (Дата обращения - 25.03.2011).</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Scadding G.K., Durham S.R., Mirakian R., Jones N.S., Leech S.C., Farooque S., et al. BSAСI guidelines for the management of allergic and non-allergic rhinitis. Clin. Exp. Allergy. 2008, v. 38, p. 19-42.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Davies R.J. Immunotherapy in respiratory allergy. Thorax. 1983, v. 38, p. 401-407.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Frankland A.W., Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. The Lancet. 1954, v. 266, No. 1 (6821), p. 1055-1057.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Lowell F.C., Franklin W. A double blind study of effectiveness and specificity of injection therapy in ragweed hay fever. N. Engl. J. Med. 1965, v. 273, p. 675-679.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Воробьева О.В., Гущин И.С. Развитие метода аллергенспецифической иммунотерапии в период 20-60-х годов XX века - до обнаружения IgE. Рос. Аллергол. Журн. 2011, № 2, с. 3-12.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Norman P.S., Lichtenstein L.M., Kagey-Sobotka A. et al. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J. Allergy Clin. Immunol. 1982, v. 70, p. 248-260.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Bousquet J., Maasch H.J., Hejjaoui A. et al. Double-blind, placebo- controlled immunotherapy with grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular- weight preparations in rhinoconjunctivitis and asthma. J. Allergy Clin. Immunol. 1989, v. 84, p. 546-556.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Olsen O.T., Larsen K.R., Jacobsen L. et al. A 1-year, placebocontrolled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy. 1997, v. 52, p. 853-859.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Litwin A., Flanagan M., Entis G. et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J. Allergy Clin. Immunol. 1997, v. 100, p. 30-38.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Naclerio R.M., Proud D., Moylan B. et al. A double-blind study of the discontinuation of ragweed immunotherapy. J. Allergy Clin. Immunol. 1997, v. 100, p. 293-300.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Adkinson N.F., Eggleston P.A., Eney D. et al. A controlled trial of immunotherapy for asthma in allergic children. 1997, v. 336, p. 324-332.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Passalacqua G., Albano M., Riccio A.M. et al. Clinical and immunological effects of a rush sublingual immunotherapy to Parietaria species: a double-blind placebo-controlled trial. J. Allergy Clin. Immunol. 1999, v. 104, p. 964-968.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Walker S.M., Pajno G.B., Torres Lima M. et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial. J. Allergy Clin. Immunol. 2001, v. 107, p. 87-93.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Pajno G.B., Morabito L., Barberio G. et al. Clinical and immunological effects of long-term sublingual immunotherapy in asthmatic children sensitized to mite: a double blind study. Allergy. 2002, v. 55, p. 842-849.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Torres L., Wilson D. et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trials. Clin. Exp. Allergy. 2002, v. 32, p. 507-514.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Pajno G.B., Passalacqua G., Vita D. et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy. 2004, v. 59, p. 883-887.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Khinci M.S., Poulsen L.K. et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized placebo controlled double blind study. Allergy. 2004, v. 59, p. 45-53.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Marogna M., Spadolini I., Massolo A. et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: a clinical efficacy and more. Allergy. 2004, v. 59, p. 1205-1210.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Frew A.J., Powell R.J. et al. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2006, v. 117, p. 319-325.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Mauro M., Russello M., Incorvaia C. et al. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur. Ann. Allergy Clin. Immunol. 2007, v. 39, p. 119-122.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Marogna M., Tomassetti D., Bernasconi A. et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann. Allergy Asthma Immunol. 2008, v. 101, p. 206-211.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Abramson M.J., Puy R.M., Weiner J.M. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am. J. Resp. Crit. Care Med. 1995, v. 151, p. 969-974.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Ross R.N., Nelson H.S. et al. Effectiveness of immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind placebo controlled studies. Clin. Ther. 2000, v. 22, p. 329-341.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Ross R.N., Nelson H.S., Finegold I. Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersensitivity: a meta-analysis. Clin. Ther. 2000, v. 22, p. 351-358.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Abramson M.J., Puy R.M., Weiner J.M. Allergen immunotherapy for asthma. Cockrane Database Syst. Rev. 2003, v. 4, CD001186.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Wilson D.R., Torres L.M., Durham S.R. Sublingual immunotherapy for allergic rhinitis. Cockrane Database Syst. Rev. 2003, (2), CD002893.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Wilson D.R., Torres Lima M. et al. Sublingual immunotherapy for allergic rhinitis: Systemic review and meta-analysis. Allergy. 2005, v. 60, p. 4-12.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Olaguibel J.M., Alvarez Puebla M.J. Efficacy of sublingual allergen vaccination for respiratory allergy in children: conclusion from one meta-analysis. J. Investig. Allergol. Clin. Immunol. 2005, v. 15, p. 9-16.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Calamita Z., Saconato H., Pela A.B. et al. Efficacy of sublingual immunotherapy in asthma: a systemic review of randomized- clinical trials using the Cockrane Collaboration method. Allergy. 2006, v. 61, p. 1162-1172.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Penagos M., Passalacqua G., Compalati E. et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008, v. 133, p. 599-609.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Abramson M.J., Puy R.M., Weiner J.M. Allergen specific immunotherapy for asthma (Cockrane Review) / In: Cockrane Library. 1998. Issue 3. Oxford: Update Software.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Abramson M., Puy R., Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy. 1999, v. 54, p. 1022- 1041.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Calderon M.A., Alves B., Jacobson M. et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cockrane Database Syst. Rev. 2007, (1), CD001936.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Compalati E., Passalacqua G., Bonini M., Canonica G.W. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: result of a GA2LEN meta-analysis. Allergy. 2009, v. 64, p. 1570-1579.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Penagos M., Compalati E., Tarantini F. et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann. Allergy Asthma Immunol. 2006, v. 97, p. 141-148.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Клинические рекомендации. Аллергология / Под ред. Р.М. Хаитова, Н.И. Ильиной. М., «ГЭОТАР-Медиа». 2008, с. 193-206. Серия «Клинические рекомендации РААКИ».</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Гущин И.С., Читаева В.Г. Аллергия к насекомым: клиника, диагностика и лечение. М., «Фармарус Принт». 2003, с. 162-236.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Гущин И.С., Курбачева О.М. Аллергия и аллергенспецифическая иммунотерапия. М., «Фармарус Принт Медиа». 2010, с. 110-226.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Morris A. Allergen-specific immunotherapy - guidelines for the clinician. Allergy Society of South Africa [Электронный ресурс]: http://www.allergysa.org/immuno.htm (Дата обращения - 16.06.2008).</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Sabbah A., Hassoun S., Le Sellin J. et al. A double-blind, placebo- controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy. 1994, v. 49, p. 309-313.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Scadding G.K., Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin. Allergy. 1986, v. 16, p. 483-491.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Tari M.G., Mancino M., Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol. Immunopathol.(Madr.). 1990, v. 18, p. 277-284.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Gidaro G.B., Marcucci F., Sensi L. et al. The safety of sublingual- swallow immunotherapy: an analysis of published studies. Clin. Exp. Allergy. 2005, v. 35, p. 565-571.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Erny-Albrecht K. et al. Sublingual immunotherapy in allergic rhinitis and asthma: a review of recent clinical evidence. J. Appl. Res. 2007, v. 7, p. 17-31.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Bucantz S.C., Bagg A.S., and Lockey R.F. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy. In: Allergens and Allergen Immunotherapy. Ed. by R.F. Lockey, D.K. Ledford. 4th ed. Clinical Allergy and Immunology Series. Vol. 21. Informa Healthcare USA Inc. 2008, p. 455-468.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Passalacqua G., Valovirta E. Adverse effects associated with sublingual immunotherapy. In: Allergens and Allergen Immunotherapy. Ed. by R.F. Lockey, D.K. Ledford. 4th ed. Clinical Allergy and Immunology Series. V. 21. Informa Healthcare USA Inc. 2008, p. 469-476.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Lockey R.F., Benedict L.M., Turkeltaub P.C. et al. Fatalities from immunotherapy (IT) and skin testing (ST). J. Allergy Clin. Immunol. 1987, v. 79, p. 660-677.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Reid M.J., Lockey R.F., Turkeltaub P.C. et al. Survey of fatalities from skin testing and immunotherapy 1985-1989. J. Allergy Clin. Immunol. 1993, v. 92, p. 6-15.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Bernstein D.I., Wanner M., Borish L., Liss G.M. and the Immunotherapy Committee of the AAAAI. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 2004, v. 113, p. 1129-1136.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>The Committee on the Safety of Medicine (CSM) Update: Desensitizing vaccines. Br. Med. J. 1986, v. 293, p. 948.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Luederitz-Puchel U., Haustein D. Incidents following hyposensitization. Muench. med. Wschr. 1996, v. 138, p. 1-7.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Amin H.S., Liss G.M., Bernstein D.I. Evaluation of near-fatal reactions in allergen immunotherapy injections. J. Allergy Clin. Immunol. 2006, v. 117, p. 169-175.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Ragusa F.V., Passalacqua G., Gambardella R. et al. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. J. Investig. Allergol. Clin. Immunol. 1997, v. 7, p. 151-154.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Ragusa F.V., Massolo A. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Allerg. Immunol. (Paris). 2004, v. 36, p. 52-55.</mixed-citation></ref></ref-list></back></article>
